摘要
目的分析Gilbert综合征(GS)与Crigler-Najjar综合征Ⅱ型(CN-2)患者UGT1A1基因突变位点、单倍型及双倍型的差异。方法回顾性分析2010年1月1日—2019年12月31日就诊于首都医科大学附属北京佑安医院的138例GS与CN-2患者临床资料,其中GS组109例,CN-2组29例,分析两种表型在突变位点上的差异。计量资料两组间比较采用Mann-Whitney U检验。计数资料两组间比较采用χ^(2)检验或Fisher精确检验。使用SNPStats软件对突变位点进行连锁不平衡(LD)分析及单倍型分析。强LD被定义为|D′|和r^(2)均>0.8,中度LD被定义为|D′|>0.8且r^(2)>0.4。结果138例患者均进行了UGT1A1基因检测,突变主要发生在启动子上游苯巴比妥反应增强元件(PBREM)区域-3279T>G突变(104例,75.36%)、-3152G>A突变(82例,59.42%)和启动子TATA盒TA插入突变(88例,63.77%),以及编码区1号外显子上的c.211 G>A突变(66例,47.83%)。GS组在PBREM区域-3279T>G位点(82.57%vs 48.28%,χ^(2)=14.508,P<0.001)、-3152G>A位点(68.81%vs 24.14%,χ^(2)=18.955,P<0.001)及启动子TATA盒(TA)_(6)>(TA)_(7)突变的比例(72.48%vs 31.03%,χ^(2)=17.027,P<0.001)均明显高于CN-2组,而CN-2组在c.211位点(68.97%vs 42.20%,χ^(2)=6.575,P=0.010)和c.1456位点(51.72%vs 7.34%,χ^(2)=29.372,P<0.001)的突变比例显著高于GS组。对UGT1A1基因不同突变位点的LD分析发现,(TA)_(6)>(TA)_(7)与-3152G>A之间存在强LD(|D′|>0.8,r^(2)>0.8),在(TA)_(6)>(TA)_(7)和-3279T>G、-3152G>A和-3279T>G、(TA)_(6)>(TA)_(7)和c.211G>A、-3279T>G和c.211G>A之间存在中度LD(|D′|均>0.8,r^(2)均>0.4)。单倍型频率分析发现在GS组中单倍型-3279G—-3152A—(TA)_(7)出现的频率高于CN-2组(45.72%vs 17.24%,χ^(2)=7.833,P=0.005),而c.1456G(4.10%vs 16.48%,χ^(2)=4.873,P=0.027)和c.211A—c.1456G(1.86%vs 24.90%,χ^(2)=15.210,P<0.001)的频率低于CN-2组。双倍型分析发现单倍型c.1456G和c.211A—c.1456G参与组成的双倍型对应更高的TBil水平。结论GS和CN-2患者的常见UGT1A1基因突变位点以及主要单倍型不同,CN-2常见双倍型对应更高的TBil水平。
Objective To investigate the differences in UGT1A1 gene mutation sites,haplotypes,and diplotypes between patients with Gilbert syndrome(GS)and those with Crigler-Najjar syndrome type II(CN-2).Methods A retrospective analysis was performed for the clinical data of 138 patients with GS or CN-2 who attended Beijing YouAn Hospital,Capital Medical University,from January 1,2010 to December 31,2019,with 109 patients in the GS group and 29 patients in the CN-2 group,and the differences in mutation sites were analyzed between the two phenotypes.The Mann-Whitney U test was used for comparison of continuous data between two groups,and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups.SNPStats software was used to perform linkage disequilibrium(LD)and haplotype analyses of mutation sites.Strong LD was defined as both|D′|and r^(2)>0.8,and moderate LD was defined as|D′|>0.8 and r^(2)>0.4.Results UGT1A1 gene detection was performed for all patients,and mutations mainly included-3279T>G mutation(104 patients,75.36%)and-3152G>A mutation(82 patients,59.42%)in the upstream promoter PBREM region,a promoter TATA box TA insertion mutation(88 patients,63.77%),and c.211G>A mutation in Exon 1 of the coding region(66 patients,47.83%).Compared with the CN-2 group,the GS group had a significantly higher proportion of PBREM region-3279T>G mutation(82.57%vs 48.28%,χ^(2)=14.508,P<0.001),PBREM region-3152G>A mutation(68.81%vs 24.14%,χ^(2)=18.955,P<0.001),and promoter TATA box(TA)_(6)>(TA)_(7)mutation(72.48%vs 31.03%,χ^(2)=17.027,P<0.001),and compared with the GS group,the CN-2 group had a significantly higher proportion of mutations at the c.211 locus(68.97%vs 42.20%,χ^(2)=6.575,P=0.010)and the c.1456 locus(51.72%vs 7.34%,χ^(2)=29.372,P<0.001).LD analysis of different mutation sites of the UGT1A1 gene showed strong LD(|D′|>0.8,r^(2)>0.8)between(TA)_(6)>(TA)_(7)and-3152G>A and moderate LD(|D′|>0.8,r^(2)>0.4)between(TA)_(6)>(TA)_(7)and-3279T>G,between-3152G>A and-3279T>G,between(TA)_(6)>(TA)_(7)and c.211G>A,and between-3279T>G and c.211G>A.Haplotype frequency analysis showed that compared with the CN-2 group,the GS group had a significantly higher frequency of haplotype-3279G—-3152A—(TA)_(7)(45.72%vs 17.24%,χ^(2)=7.833,P=0.005)and significantly lower frequencies of c.1456G(4.10%vs 16.48%,χ^(2)=4.873,P=0.027)and c.211A—c.1456G(1.86%vs 24.90%,χ^(2)=15.210,P<0.001).The diplotype analysis showed that diplotypes consisting of haplotype c.1456G or c.211A—c.1456G were associated with a higher level of total bilirubin(TBil).Conclusion There are differences in common mutation sites and major haplotypes of the UGT1A1 gene between patients with GS and those with CN-2,and the common diplotypes of CN-2 correspond to a higher level of TBil.
作者
刘念晨
白洁
梁晨
白丽
刘霜
段钟平
郑素军
LIU Nianchen;BAI Jie;LIANG Chen;BAI Li;LIU Shuang;DUAN Zhongping;ZHENG Sujun(First Department of Liver Disease Center,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China;Fourth Department of Liver Disease Center,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China;Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research,Beijing 100069,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2022年第2期397-401,共5页
Journal of Clinical Hepatology
基金
北京市医院管理中心重点医学专业发展计划建设任务书(ZYLX202125)
北京市医院管理局消化内科学科协同发展中心项目(XXZ0503)。